Genomics plc, a UK-based precision healthcare technology developer backed by drug manufacturer Vertex Pharmaceuticals, closed a $30m funding round on Monday.
F-Prime Capital, an investment affiliate of financial services and investment group Fidelity, provided the funding together with university venture fund Oxford Sciences Innovation (OSI), Foresite Capital and Lansdowne Partners.
Founded in 2014, Genomics has developed a machine learning-powered genomic analytics platform that determines the risk of individuals for common diseases before they manifest.
Apart from delivering its population health management services and clinical decision support tools, the company also uses its insights to support the discovery and development of treatments. It will use the equity financing to expand its platform.
Genomics closed a $41.7m series B round in 2018 backed by Vertex Pharmaceuticals, OSI, commercialisation firm IP Group, F-Prime Capital, Foresite Capital, Landsdowne Partners, Invesco Perpetual, Tanarra and the now-defunct Woodford Investment Management.
University of Oxford had contributed to the company’s $16.2m series A round in 2014 together with IP Group and its IP Venture Fund II, as well as Invesco Perpetual, Lansdowne Partners, Woodford Investment Management and Wylie Family Trust.
The original version of this article appeared on our sister site, Global University Venturing.